Preconditioning and Cellular Engineering to Increase the Survival of Transplanted Neural Stem Cells for Motor Neuron Disease Therapy.

Amyotrophic lateral sclerosis Cellular engineering Motor neuron diseases Neural stem cells Preconditioning Spinal muscular atrophy Stem cell transplantation Stem cells

Journal

Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963

Informations de publication

Date de publication:
May 2019
Historique:
received: 13 05 2018
accepted: 07 08 2018
pubmed: 19 8 2018
medline: 21 8 2019
entrez: 19 8 2018
Statut: ppublish

Résumé

Despite the extensive research effort that has been made in the field, motor neuron diseases, namely, amyotrophic lateral sclerosis and spinal muscular atrophies, still represent an overwhelming cause of morbidity and mortality worldwide. Exogenous neural stem cell-based transplantation approaches have been investigated as multifaceted strategies to both protect and repair upper and lower motor neurons from degeneration and inflammation. Transplanted neural stem cells (NSCs) exert their beneficial effects not only through the replacement of damaged cells but also via bystander immunomodulatory and neurotrophic actions. Notwithstanding these promising findings, the clinical translatability of such techniques is jeopardized by the limited engraftment success and survival of transplanted cells within the hostile disease microenvironment. To overcome this obstacle, different methods to enhance graft survival, stability, and therapeutic potential have been developed, including environmental stress preconditioning, biopolymers scaffolds, and genetic engineering. In this review, we discuss current engineering techniques aimed at the exploitation of the migratory, proliferative, and secretive capacity of NSCs and their relevance for the therapeutic arsenal against motor neuron disorders and other neurological disorders.

Identifiants

pubmed: 30120734
doi: 10.1007/s12035-018-1305-4
pii: 10.1007/s12035-018-1305-4
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

3356-3367

Subventions

Organisme : Ministero della Salute
ID : 02362317
Organisme : AFM-Téléthon
ID : Optimized Transplantation of hiPSC derived LeX+CXCR4+VLA4 neural stem cells as a therapy for SMARD1
Organisme : FP7 People: Marie-Curie Actions
ID : 612578

Références

Proc Natl Acad Sci U S A. 1999 May 11;96(10):5768-73
pubmed: 10318959
J Neurosci. 2001 Sep 15;21(18):7153-60
pubmed: 11549726
Nat Med. 2002 Sep;8(9):963-70
pubmed: 12161747
Ann Neurol. 2003 Jun;53(6):743-51
pubmed: 12783420
Stem Cells. 2003;21(4):405-16
pubmed: 12832694
NeuroRx. 2004 Oct;1(4):472-81
pubmed: 15717048
Neurosurgery. 2005 Aug;57(2):325-33; discussion 325-33
pubmed: 16094163
Brain Res. 2005 Dec 14;1065(1-2):8-19
pubmed: 16309635
Hum Mol Genet. 2006 Jan 15;15(2):167-87
pubmed: 16339214
J Comp Neurol. 2006 Jul 20;497(3):468-88
pubmed: 16736475
Stroke. 2007 Feb;38(2 Suppl):817-26
pubmed: 17261746
Stem Cells Dev. 2007 Aug;16(4):579-88
pubmed: 17784831
Nat Neurosci. 2008 Mar;11(3):251-3
pubmed: 18246065
Exp Neurol. 2008 Apr;210(2):656-70
pubmed: 18279854
Neurosci Lett. 2008 Oct 31;444(3):227-30
pubmed: 18760326
Brain Res. 2009 Aug 11;1284:1-11
pubmed: 19520066
Brain. 2010 Feb;133(Pt 2):465-81
pubmed: 20032086
Stem Cells. 2010 Mar 31;28(3):545-54
pubmed: 20073084
Neurorehabil Neural Repair. 2010 Sep;24(7):636-44
pubmed: 20424193
Neurosci Lett. 2011 May 2;494(3):222-6
pubmed: 21402124
J Int Med Res. 2011;39(2):488-98
pubmed: 21672352
J Neurosci. 2012 Mar 7;32(10):3462-73
pubmed: 22399769
Stem Cells. 2012 Jun;30(6):1144-51
pubmed: 22415942
Neurobiol Dis. 2012 Jun;46(3):635-45
pubmed: 22426403
Neurosurgery. 2012 Aug;71(2):405-16; discussion 416
pubmed: 22565043
Stroke. 2012 Sep;43(9):2423-9
pubmed: 22713489
Cell Transplant. 2013;22(8):1441-52
pubmed: 23044072
J Neuroimmunol. 2013 Jan 15;254(1-2):83-90
pubmed: 23084372
Brain. 2012 Nov;135(Pt 11):3298-310
pubmed: 23169920
Sci Transl Med. 2012 Dec 19;4(165):165ra164
pubmed: 23253611
Exp Neurol. 2014 Oct;260:44-9
pubmed: 23376590
Transl Stroke Res. 2013 Feb;4(1):76-88
pubmed: 23914259
Hum Mol Genet. 2014 Jan 15;23(2):342-54
pubmed: 24006477
Cell Transplant. 2014;23(12):1585-97
pubmed: 24070071
Cell Mol Life Sci. 2014 Mar;71(6):999-1015
pubmed: 24100629
Brain Struct Funct. 2015 Jan;220(1):361-83
pubmed: 24178679
Ann Neurol. 2014 Mar;75(3):363-73
pubmed: 24510776
Cell Transplant. 2015;24(12):2449-61
pubmed: 24594369
Cell Mol Life Sci. 2014 Sep;71(17):3257-68
pubmed: 24699704
Stem Cell Reports. 2014 Aug 12;3(2):297-311
pubmed: 25254343
Ann Clin Transl Neurol. 2014 Nov;1(11):900-8
pubmed: 25540804
Recent Pat Drug Deliv Formul. 2015;9(2):158-66
pubmed: 25612744
Exp Neurol. 2015 Oct;272:78-87
pubmed: 25797577
Neuropsychopharmacology. 2015 Sep;40(10):2368-78
pubmed: 25833129
Mol Neurobiol. 2016 May;53(4):2124-31
pubmed: 25934102
Recent Pat Endocr Metab Immune Drug Discov. 2015;9(2):63-73
pubmed: 26510796
J Cereb Blood Flow Metab. 2016 Dec;36(12):2134-2145
pubmed: 26661220
Ann Neurol. 2016 Mar;79(3):342-53
pubmed: 26696091
Cell Transplant. 2016;25(5):797-809
pubmed: 26766038
Cell Mol Life Sci. 2016 Jun;73(11-12):2251-67
pubmed: 27048812
Hum Mol Genet. 2016 Aug 1;25(15):3152-3163
pubmed: 27270413
Neurology. 2016 Jul 26;87(4):392-400
pubmed: 27358335
Biomaterials. 2016 Oct;105:145-155
pubmed: 27521617
Exp Neurol. 2017 Mar;289:96-102
pubmed: 28038988
Stem Cells Dev. 2017 Apr 15;26(8):554-565
pubmed: 28103744
J Cereb Blood Flow Metab. 2017 Jul;37(7):2314-2319
pubmed: 28303738
Biomaterials. 2017 Aug;136:1-11
pubmed: 28505596
Lancet Neurol. 2017 Jul;16(7):505-512
pubmed: 28522181
Prog Brain Res. 2017;230:99-132
pubmed: 28552237
Biomaterials. 2017 Oct;142:31-40
pubmed: 28719819
Cell Rep. 2017 Aug 22;20(8):1964-1977
pubmed: 28834757
J Cell Biochem. 2018 Jun;119(6):4339-4351
pubmed: 28884834
Stroke Vasc Neurol. 2016 Oct 25;1(3):101-107
pubmed: 28959470
Nat Rev Dis Primers. 2017 Oct 20;3:17085
pubmed: 29052611
Stem Cell Res Ther. 2017 Nov 7;8(1):248
pubmed: 29115993
Stem Cell Res. 2017 Dec;25:166-178
pubmed: 29154076
Int J Mol Sci. 2018 Jan 05;19(1):null
pubmed: 29304004
Ther Adv Neurol Disord. 2018 Feb 05;11:1756285618754501
pubmed: 29434670
Nature. 2018 Mar 15;555(7696):377-381
pubmed: 29513649
Oncotarget. 2018 Jan 31;9(12):10621-10634
pubmed: 29535831
Sci Rep. 2018 Mar 14;8(1):4513
pubmed: 29540727
Cell Stem Cell. 2018 Apr 5;22(4):589-599.e5
pubmed: 29625071
Stem Cells. 2018 Jul;36(7):1122-1131
pubmed: 29656478
J Biomed Nanotechnol. 2018 Jun 1;14(6):1075-1089
pubmed: 29843872
Stem Cells Dev. 2018 Aug 15;27(16):1085-1096
pubmed: 29893190
Ann Clin Transl Neurol. 2018 May 02;5(6):730-740
pubmed: 29928656
J Comp Neurol. 1965 Jun;124(3):319-35
pubmed: 5861717
Lancet. 1996 May 25;347(9013):1425-31
pubmed: 8676624
Nature. 1997 Apr 3;386(6624):493-5
pubmed: 9087407
Eur J Neurosci. 1998 Jun;10(6):2026-36
pubmed: 9753090
Nat Med. 1998 Nov;4(11):1313-7
pubmed: 9809557

Auteurs

Elena Abati (E)

Dino Ferrari Centre, Department of Pathophysiology and Transplantation (DEPT), Neuroscience Section, University of Milan, Milan, Italy.

Nereo Bresolin (N)

Dino Ferrari Centre, Department of Pathophysiology and Transplantation (DEPT), Neuroscience Section, University of Milan, Milan, Italy.
Neurology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, via F. Sforza 35, 20122, Milan, Italy.

Giacomo Pietro Comi (GP)

Dino Ferrari Centre, Department of Pathophysiology and Transplantation (DEPT), Neuroscience Section, University of Milan, Milan, Italy.
Neurology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, via F. Sforza 35, 20122, Milan, Italy.

Stefania Corti (S)

Dino Ferrari Centre, Department of Pathophysiology and Transplantation (DEPT), Neuroscience Section, University of Milan, Milan, Italy. stefania.corti@unimi.it.
Neurology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, via F. Sforza 35, 20122, Milan, Italy. stefania.corti@unimi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH